Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Suzhou CStone Pharma Engages Goldman Sachs to Explore Sale of Company

publication date: Jul 15, 2022

CStone Pharma of Suzhou is reported to be exploring strategic options for the company, which could include sale of the entire company or a majority stake, according to a report from Bloomberg News. The company reported working capital of US$130 million at 2021 year-end, almost two-thirds lower than the year earlier. CStone in-licenses drugs for China use and develops its own products. The company is at the awkward stage when the number of clinical trials is high, but revenues from approved drug isn’t keeping pace. The Bloomberg report said CStone has hired Goldman Sachs to analyze its options. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital